GlassScriptPhysician profile
Manuel Garza
NPI 1245859677
$1,955.72
in general payments reported to CMS, 2019-2025
14 companies · $851 in 2025
The $851 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $96.10 · 2024: $1,009 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $641.99 | 2024-2025 | |
| Lilly USA, LLC | $227.07 | 2024 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $221.00 | 2024 | Zeposia |
| Gilead Sciences, INC. | $148.17 | 2024-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.99 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $124.98 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $121.52 | 2025 | Entyvio |
| Mallinckrodt Hospital Products INC. | $56.75 | 2025 | Terlivaz |
| Janssen Biotech, INC. | $54.02 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $38.09 | 2025 | Rezdiffra |
| Pfizer INC. | $22.90 | 2024 | |
| Genzyme Corporation | $20.76 | 2024 | |
| Olympus America INC. | $20.09 | 2025 | Evis Exera III Colonovideoscope |
| Aimmune Therapeutics, INC. | $17.29 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.